CTLA4 and neoplasm: When these signals are blocked, e.g., by ipilimumab targeting CTLA-4, or nivolumab and pembrolizumab targeting PD-1, T-cells remain active, proliferate, secrete cytokines and induce lysis of tumor cells [15].